AusBiotech CEO Anna Lavelle stepping down
The CEO of AusBiotech, Dr Anna Lavelle, will hand over leadership of the organisation after more than 11 years of service to the Australian biotechnology industry.
She will continue at AusBiotech in the role of principal advisor to the board, while the role of CEO will be taken up by the company’s current chief operating officer, Glenn Cross.
Dr Lavelle has been praised by AusBiotech Chairman Julie Phillips, who described her as “respected, visionary and eminent, as well as talented, tenacious and a dedicated advocate for our industry”.
“AusBiotech has gone from strength to strength under Anna’s leadership,” said Phillips. “Of the many achievements we saw during her time as CEO, the delivery to the industry of the landmark reform, the Research and Development (R&D) Tax Incentive, is a highlight. Anna is quite rightly proud of her part in delivering this initiative which delivered hundreds of millions of dollars to the sector in cash as tax refunds — this among other many things, we each have to thank her for.”
Incoming CEO Glenn Cross has spent most of his working life in life sciences, having been a founder of DePuy Australia, the first employee of Becton Dickinson Australia, CEO of Vision Systems Instrumentation and more. He has been with AusBiotech for over a decade and has achieved a great deal, such as encouraging investor interest in Australian technology and being pivotal in increasing focus in Australian medical technologies.
Lorraine Chiroiu will meanwhile assume the role of deputy CEO after almost eight years as national communications manager and more recently as chief industry affairs officer. The new appointments will commence on 1 September.
“The board is delighted to welcome Glenn and Lorraine to their new roles,” said Phillips.
“The board is confident that the new arrangement will provide a smooth transition and continued strong leadership team for AusBiotech as it works to progress the growth of the Australian life sciences industry.”
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
RNA-targeted therapy shows promise for childhood dementia
Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...
Parkinson's alters emotion-related bodily sensations
People with Parkinson's disease were found to have significant differences in all bodily...
